Sep 152016
 

By Talent4Boards Team

Talent4Boards – Great Talent builds Great Boards

– FRANCE, Paris – Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral technology that allows a safe local sustained production of therapeutic proteins in the eye to address a wide range of ophthalmic diseases, announces that the total Capital Raised in the Series A is €9 million.… => Read more

Eyevensys adds Ohad Hammer to its Board along with closing its €9m Series A funding round

From:: Eyevensys adds Ohad Hammer to its Board along with closing its €9m Series A funding round

Sorry, the comment form is closed at this time.

%d bloggers like this: